Open AccessCIBMTR Analysis Confirms Ongoing Role for Autologous Transplant in Chemosensitive Relapsed DLBCL
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0554
Subject(s) - medicine , oncology , lymphoma , diffuse large b cell lymphoma , bone transplantation , refractory (planetary science) , chimeric antigen receptor , hematopoietic cell , bone marrow transplant , bone marrow , bone marrow transplantation , surgery , cancer , stem cell , immunotherapy , haematopoiesis , biology , genetics , astrobiology
In the era of chimeric antigen receptor (CAR) T‐cell therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant Research (CIBMTR) confirms an ongoing role for autologous transplant in patients with chemosensitive relapsed DLBCL.